Friday, August 7, 2009

Two Technologies one Company, Best Deal on the OTC.

AlumiFuel Power Corporation, formerly known as Inhibiton Therapeutics, Inc., recently acquired the wholly owned operating subsidiary AlumiFuel Power, Inc., a Philadelphia-based early production stage alternative energy company that generates hydrogen gas and steam for multiple niche applications requiring on-site, on-demand fuel sources. The Company also has been conducting biotechnology research, development and potential commercialization of technologies and products for new cancer therapeutic agents and cancer fighting drugs called targeted therapies.

AFPW.OB is clearly a company on the move, recent press releases tell of quad tripling of laboratory space. First product to begin initial production. The hiring of new investor relations. The strong management and numerous niche markets make Alumifuel Power Corp a very attractive investment.

Want More? Check out the new Investor Relations website -http://irgnews.com/coi/AFPW

Web-site- http://www.alumifuelpowerinc.com/

Thursday, July 16, 2009

AlumiFuel Power Corp. Operating Subsidiary AlumiFuel Power, Inc. Customizes Its Powder Mixtures Through Nanotechnology Analysis.

Press Release Source: AlumiFuel Power Corporation On Thursday July 16, 2009,

CENTENNIAL, Colo.--(BUSINESS WIRE)--AlumiFuel Power Corporation (“the Company”) (OTCBB: AFPW) said today that its wholly owned operating subsidiary, AlumiFuel Power, Inc. (“API”), based in Philadelphia, Pennsylvania, an early production stage hydrogen generation company, has announced new breakthroughs in its AlumiFuel powdered aluminum mixes for specific applications as a result of nanotechnology materials analysis made possible by its membership in Drexel University’s Nanotechnology Consortium and the resultant direct interaction with the Drexel Nanotechnology Institute (DNI).
As a member of the Drexel Nanotechnology Consortium, API has access to the world-class Central Research Facilities of Drexel University, including state-of-the-art analytical and imaging labs and a micro fabrication lab. The labs rely on a vast array of advanced equipment for electron microscopy, spectroscopy, x-ray diffraction, micro fabrication and other nanoscale functions.
The Drexel relationship has given API cutting edge capabilities to analyze, at the atomic level, pre- and post-reacted AlumiFuel powder mixtures and to observe small samples during the reaction. This technology allows for very precise observations of the fundamental chemical mechanisms that accelerate or decelerate the reaction, which will ultimately lead to more controllability and higher yields. API has processed dozens of images and spectrographs capturing the variety of crystal growth occurring during the reaction and also the shape, size and surface characteristics of the aluminum before the reaction
API’s Chief Technology Officer, Mr. John Boyle, a nationally renowned hydrogen expert, said, “These observations already have helped API tailor the size, shape and dispersion of AlumiFuel mixtures for various applications -- ranging from a rapid low temperature release of hydrogen for inflating weather balloons, to a slower steady release of hydrogen for fuel cells to generate electricity or a high temperature reaction to power steam turbines for underwater propulsion
As a result of this synergy, API and DNI are also collaborating in the pursuit of various Department of Defense R&D program opportunities, with DNI serving as a subcontractor to API on selected Small Business Technology Transfer and Small Business Innovative Research proposals.
API’s President & CEO, Mr. David Cade, said, “We are extremely fortunate to have such a close working relationship with Drexel Engineering. This has enabled API to more aggressively pursue our business plan as we commercialize our technology and penetrate our target markets.”

STRONG BUY!

Monday, July 6, 2009

Inhibiton Therapeutics Completes Name Change to AlumiFuel Power Corporation

Company to Begin Trading Under Symbol “AFPW” on OTC Bulletin Board at Market Open on July 6, 2009

Thursday, June 4, 2009


Press Release.

Inhibiton Therapeutics Inc. stockholders have approved a name change to AlumiFuel Power Corp., the company announced Thursday.
The renaming follows Centennial-based Inhibiton's acquisition of HPI Partners LLC and its subsidiary, AlumiFuel Power Inc.
"We believe given the immediate impact API will have on the company it makes sense to identify the public entity with that operating subsidiary to provide continuity for our shareholders, interested investors and the alternative energy community," Henry Fong, president of Inhibiton (OTCBB: IHBT), said last month when the proposed name change was announced.
"We are continuing to pursue our biotechnology research project; however, the board also intends to investigate strategic alternatives available to the company with respect to the two separate business divisions," Fong said then.
The company's symbol will change on the OTC Bulletin Board.
The purchase signaled that Inhibiton is branching out from its prior focus on biotechnology research on fighting cancer.
Inhibiton's all-stock deal for HPI Partners and AlumiFuel Power was worth $12 million, Inhibiton said when it was announced in December.
HPI and AlumiFuel are based in Philadelphia. AlumiFuel is an alternative-energy company seeking to commercialize a process for generating hydrogen gas and steam, to be used where onsite, on-demand fuel sources are needed.
The deal calls for members of HPI to receive up to $12 million of Inhibiton’s stock in exchange for all interest in HPI, including ownership of AlumiFuel, its intellectual property and business operations.
AlumiFuel processes generate hydrogen gas and steam, which drive fuel cells for backup and portable power, filling inflatable devices such as weather balloons.